Koers CELK AB Nasdaq Stockholm
Aandelen
SE0009189657
Geavanceerde medische apparatuur & technologie
Omzet 2024 * | 2,43 mld. 229 mln. 0 214 mln. | Omzet 2025 * | 2,78 mld. 262 mln. 0 244 mln. | Marktkapitalisatie | 3,1 mld. 292 mln. 0 273 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -74 mln. -6,97 mln. - -6,51 mln. | Nettowinst (verlies) 2025 * | -16 mln. -1,51 mln. - -1,41 mln. | EV/omzet 2024 * | 1,02 x |
Nettoliquiditeiten 2024 * | 630 mln. 59,37 mln. 0 55,44 mln. | Nettoliquiditeiten 2025 * | 311 mln. 29,28 mln. 0 27,34 mln. | EV/omzet 2025 * | 1,01 x |
K/w-verhouding 2024 * |
-41,5
x | K/w-verhouding 2025 * |
-191
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 60,54% |
Recentste transcriptie over CELK AB
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Chief Executive Officer | 52 | 20/11 | |
Director of Finance/CFO | 39 | 01-12-21 | |
Marius Balger
COO | Chief Operating Officer | 56 | 01-03-23 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Rolf Classon
CHM | Chairman | 79 | 26-04-22 |
John Mackay
BRD | Director/Board Member | 62 | 01-01-23 |
Director/Board Member | 68 | 18-12-19 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+4,28% | 213 mld. | |
+9,06% | 188 mld. | |
+31,43% | 157 mld. | |
+33,03% | 113 mld. | |
+5,25% | 64,85 mld. | |
+22,22% | 55,17 mld. | |
+1,34% | 49,1 mld. | |
-5,03% | 38,83 mld. | |
+1,97% | 35,6 mld. |